Filtered By:
Specialty: Cancer & Oncology
This page shows you your search results in order of date. This is page number 17.
Order by Relevance | Date
Total 124205 results found since Jan 2013.
Potential Medical Use of Fullerenols After Two Decades of Oncology Research
Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231201515. doi: 10.1177/15330338231201515.ABSTRACTFullerenes are carbon molecules that are found in nature in various forms. They are composed of hexagonal and pentagonal rings that create closed structures. Almost 4 decades ago, fullerenes were identified in the form of C60 and C70, and following the award of the Nobel Prize in Chemistry for this discovery in 1996, many laboratories started working on their water-soluble derivatives that could be used in different industries, including pharmaceutical industries. One of the first fullerene forms that was the focus of differ...
Source: Technology in Cancer Research and Treatment - September 19, 2023 Category: Cancer & Oncology Authors: Rade Injac Source Type: research
TACE Combined with Lenvatinib and Camrelizumab for Unresectable Multiple Nodular and Large Hepatocellular Carcinoma ( & gt;5 cm)
CONCLUSIONS: In patients with unresectable multiple nodular and large HCC (single nodular diameter of >5 cm), TACE combined with target therapy and immunotherapy is safe and effective.PMID:37723998 | DOI:10.1177/15330338231200320
Source: Technology in Cancer Research and Treatment - September 19, 2023 Category: Cancer & Oncology Authors: Zhanwang Xiang Guohong Li Luwen Mu Haofan Wang Churen Zhou Huzheng Yan Mingsheng Huang Source Type: research
Lobar or sublobar resection for early-stage second primary lung cancer ≤ 3 cm in size: a SEER population-based study
CONCLUSION: The OS of sublobar resection was not significantly different from that of lobar resection for early-stage SPLC. For SPLC with a 2-3 cm tumor size, lobar resection is more advantageous than sublobar resection.PMID:37725243 | DOI:10.1007/s00432-023-05396-5
Source: Clinical Lung Cancer - September 19, 2023 Category: Cancer & Oncology Authors: Ke Zhao Chunqiu Xia Minghan Qiu Zhen Yang Tingkai Cui Teng Song Shuping Li Hanwei Mei Yang Zheng Huaqing Wang Source Type: research
SLC12A8 mediates TKI resistance in EGFR-mutant lung cancer via PDK1/AKT axis
CONCLUSION: SLC12A8 mediates TKI resistance in EGFR-mutant lung cancer via PDK1/AKT axis. These findings not only advance our understanding of the molecular mechanisms driving TKI resistance, but also offer novel alternative strategies for the treatment of lung cancer.PMID:37725242 | DOI:10.1007/s00432-023-05416-4
Source: Clinical Lung Cancer - September 19, 2023 Category: Cancer & Oncology Authors: Fang Huang Jian Cui Jingxuan Wan Xue Yuan Yuanzhe Zhu Xiangxiang Wu Wei Zuo Tiantian Zhao Source Type: research
Development and validation of the CAIL prognostic score in non-small cell lung cancer patients with malignant pleural effusion
CONCLUSIONS: For NSCLC patients with MPE, the validated CAIL prognostic score integrates clinical characteristics and therapeutic modalities to predict survival.PMID:37723659 | DOI:10.1111/crj.13700
Source: Clinical Lung Cancer - September 19, 2023 Category: Cancer & Oncology Authors: Tianyuan Li Panwen Tian Qin Huang Hao Zeng Qi Wei Yalun Li Source Type: research
Proteomic landscape of primary and metastatic brain tumors for heterogeneity discovery
CONCLUSIONS AND CLINICAL RELEVANCE: We characterized an extensive proteomic landscape of BrMs and gliomas. These findings have promising implications for the development of targeted therapies for BrMs and gliomas.PMID:37726528 | DOI:10.1002/prca.202300010
Source: Clinical Genitourinary Cancer - September 19, 2023 Category: Cancer & Oncology Authors: Shuang Yang Chengbin Zhou Lei Zhang Yueting Xiong Yongtao Zheng Liuguan Bian Xiaohui Liu Source Type: research
Systematic Minigene-Based Splicing Analysis and Tentative Clinical Classification of 52 CHEK2 Splice-Site Variants
CONCLUSIONS: Incorporation of minigene read-outs into an ACMG/AMP (American College of Medical Genetics and Genomics/Association for Molecular Pathology)-based classification scheme allowed us to classify 32 CHEK2 variants (27 pathogenic/likely pathogenic and 5 likely benign). However, 20 variants (38%) remained of uncertain significance, reflecting in part the complex splicing patterns of this gene.PMID:37725924 | DOI:10.1093/clinchem/hvad125
Source: Clinical Genitourinary Cancer - September 19, 2023 Category: Cancer & Oncology Authors: Lara Sanoguera-Miralles Alberto Valenzuela-Palomo Elena Bueno-Mart ínez Ada Esteban-S ánchez V íctor Lorca In és Llinares-Burguet Alicia Garc ía-Álvarez Pedro P érez-Segura Mar Infante Douglas F Easton Peter Devilee Maaike P G Vreeswijk Miguel de l Source Type: research
Gene of the month: GATA3
J Clin Pathol. 2023 Sep 19:jcp-2023-209017. doi: 10.1136/jcp-2023-209017. Online ahead of print.ABSTRACTGATA binding protein 3 (GATA3) is a zinc-finger pioneer transcription factor involved in diverse processes. GATA3 regulates gene expression through binding nucleosomal DNA and facilitating chromatin remodelling. Post-translational modifications modulate its activity. During development, GATA3 plays a key role in cell differentiation. Mutations in GATA3 are linked to breast and bladder cancer. GATA3 expression is a feature of the luminal subtype of bladder cancer and has implications for immune status and therapeutic resp...
Source: Clinical Genitourinary Cancer - September 19, 2023 Category: Cancer & Oncology Authors: Zekai Qiang Ibrahim Jubber Kirsty Lloyd Marcus Cumberbatch Jon Griffin Source Type: research
Secondary Breast Angiosarcoma After a Primary Diagnosis of Breast Cancer: A Retrospective Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database
CONCLUSIONS: We demonstrate an increasing incidence of SBA over the study period. These data can help inform shared decision-making for optimal management of locoregional breast cancer and raise awareness of secondary angiosarcoma.PMID:37725702 | DOI:10.1097/COC.0000000000001045
Source: Clinical Genitourinary Cancer - September 19, 2023 Category: Cancer & Oncology Authors: Bonny Chau Elizabeth T Loggers Lee D Cranmer Harveshp Mogal Jeremy M Sharib Edward Y Kim Stephanie K Schaub Kelly G Paulson Hannah M Linden Jennifer M Specht Janice N Kim Sara H Javid Michael J Wagner Source Type: research
RANK expression as an independent predictor for response to neoadjuvant chemotherapy in luminal-like breast cancer - a translational insight from the GeparX trial
CONCLUSIONS: We report RANK expression to be an independent predictive biomarker for response to NACT in luminal-like breast cancer patients.PMID:37725572 | DOI:10.1158/1078-0432.CCR-23-1801
Source: Clinical Genitourinary Cancer - September 19, 2023 Category: Cancer & Oncology Authors: Theresa Link Jens-Uwe Blohmer Wolfgang D Schmitt Jan Dominik Kuhlmann Marianne Just Michael Untch Oliver Stotzer Peter A Fasching Marc Thill Mattea Reinisch Andreas Schneeweiss Pauline Wimberger Sabine Seiler Jens Huober Christian Jackisch Kerstin Rhiem C Source Type: research
Proteomic landscape of primary and metastatic brain tumors for heterogeneity discovery
CONCLUSIONS AND CLINICAL RELEVANCE: We characterized an extensive proteomic landscape of BrMs and gliomas. These findings have promising implications for the development of targeted therapies for BrMs and gliomas.PMID:37726528 | DOI:10.1002/prca.202300010
Source: Clinical Breast Cancer - September 19, 2023 Category: Cancer & Oncology Authors: Shuang Yang Chengbin Zhou Lei Zhang Yueting Xiong Yongtao Zheng Liuguan Bian Xiaohui Liu Source Type: research
Gene of the month: GATA3
J Clin Pathol. 2023 Sep 19:jcp-2023-209017. doi: 10.1136/jcp-2023-209017. Online ahead of print.ABSTRACTGATA binding protein 3 (GATA3) is a zinc-finger pioneer transcription factor involved in diverse processes. GATA3 regulates gene expression through binding nucleosomal DNA and facilitating chromatin remodelling. Post-translational modifications modulate its activity. During development, GATA3 plays a key role in cell differentiation. Mutations in GATA3 are linked to breast and bladder cancer. GATA3 expression is a feature of the luminal subtype of bladder cancer and has implications for immune status and therapeutic resp...
Source: Clinical Breast Cancer - September 19, 2023 Category: Cancer & Oncology Authors: Zekai Qiang Ibrahim Jubber Kirsty Lloyd Marcus Cumberbatch Jon Griffin Source Type: research
Systematic Minigene-Based Splicing Analysis and Tentative Clinical Classification of 52 CHEK2 Splice-Site Variants
CONCLUSIONS: Incorporation of minigene read-outs into an ACMG/AMP (American College of Medical Genetics and Genomics/Association for Molecular Pathology)-based classification scheme allowed us to classify 32 CHEK2 variants (27 pathogenic/likely pathogenic and 5 likely benign). However, 20 variants (38%) remained of uncertain significance, reflecting in part the complex splicing patterns of this gene.PMID:37725924 | DOI:10.1093/clinchem/hvad125
Source: Clinical Breast Cancer - September 19, 2023 Category: Cancer & Oncology Authors: Lara Sanoguera-Miralles Alberto Valenzuela-Palomo Elena Bueno-Mart ínez Ada Esteban-S ánchez V íctor Lorca In és Llinares-Burguet Alicia Garc ía-Álvarez Pedro P érez-Segura Mar Infante Douglas F Easton Peter Devilee Maaike P G Vreeswijk Miguel de l Source Type: research
Secondary Breast Angiosarcoma After a Primary Diagnosis of Breast Cancer: A Retrospective Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database
CONCLUSIONS: We demonstrate an increasing incidence of SBA over the study period. These data can help inform shared decision-making for optimal management of locoregional breast cancer and raise awareness of secondary angiosarcoma.PMID:37725702 | DOI:10.1097/COC.0000000000001045
Source: Clinical Breast Cancer - September 19, 2023 Category: Cancer & Oncology Authors: Bonny Chau Elizabeth T Loggers Lee D Cranmer Harveshp Mogal Jeremy M Sharib Edward Y Kim Stephanie K Schaub Kelly G Paulson Hannah M Linden Jennifer M Specht Janice N Kim Sara H Javid Michael J Wagner Source Type: research
RANK expression as an independent predictor for response to neoadjuvant chemotherapy in luminal-like breast cancer - a translational insight from the GeparX trial
CONCLUSIONS: We report RANK expression to be an independent predictive biomarker for response to NACT in luminal-like breast cancer patients.PMID:37725572 | DOI:10.1158/1078-0432.CCR-23-1801
Source: Clinical Breast Cancer - September 19, 2023 Category: Cancer & Oncology Authors: Theresa Link Jens-Uwe Blohmer Wolfgang D Schmitt Jan Dominik Kuhlmann Marianne Just Michael Untch Oliver Stotzer Peter A Fasching Marc Thill Mattea Reinisch Andreas Schneeweiss Pauline Wimberger Sabine Seiler Jens Huober Christian Jackisch Kerstin Rhiem C Source Type: research
